Ankita Gupta

Ankita Gupta

Auto-generated profile, based on publicly available information

Ankita Gupta

Department of Radiotherapy and Oncology, Post Graduate Institute of Medical education and Research, Chandigarh, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
PGParikshaa Gupta
Parikshaa Gupta
GKGargi Kapatia
Gargi Kapatia
NGNalini Gupta
Nalini Gupta
PDPranab Dey
Pranab Dey
MRManish Rohilla
Manish Rohilla
RSRadhika Srinivasan
Radhika Srinivasan
Background: Small cell carcinoma of ovary (SCCO) is extremely rare. Two types of SCCO are recognized, the pulmonary type (SCCOPT) and the hypercalcemic type (SCCOHT). Establishing an accurate diagnosis is challenging, owing to its rarity and paucity of data describing the distinctive histopathologic and immunohistochemical (IHC) features. Methods: This was a retrospective study conducted over a period of 4 years. All cases reported as SCCO on histopathology were retrieved. All the available clinical, histopathological, and IHC features were studied in detail. Results: A total of 7 cases of SCCO were diagnosed during the study period. There were 4 cases of SCCOPT and 3 cases of SCCOHT and with mean age of 57.25 and 22 years, respectively. All the cases presented as stage IV disease. Among the SCCOPT cases, 3 showed bilateral involvement with 1 showing concurrent uterine endometrioid adenocarcinoma. Microscopy revealed small hyperchromatic cells with brisk mitosis and multifocal necrosis. On IHC, these were consistently positive for chromogranin, CD56, and synaptophysin. All the SCCOHT cases showed unilateral involvement. Microscopically, in addition to small hyperchromatic cells, larger “rhabdoid” tumor cells were also seen. On IHC, chromogranin was negative, with positivity for vimentin and epithelial membrane antigen. The expression of SMARCA4/BRG1 was lost while SMARCB1/INI1 was retained in all cases. All of these patients developed recurrence and died due to disease progression despite treatment. Conclusions: SCCO is an extremely infrequent ovarian malignancy with poor prognosis. Knowledge about its characteristic features is important for accurate tissue diagnosis and appropriate management.

1 January 2019 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
RGRohit Goyal
Rohit Goyal
AGAnkita Gupta
Ankita Gupta
ASAshish Sharma
Ashish Sharma
AKanil kumar
anil kumar
OBJECTIVE: The present study aims to investigate the role of caveolin-1 in dementia of Alzheimer's type using intracerebroventricular streptozotocin (ICV-STZ)-induced neurodegeneration model in rats. MATERIALS AND METHODS: Male Wistar rats (220–260 g) were employed. STZ 3 mg/kg via ICV route was given once to cause neuronal injury. Daidzein – a caveolin inhibitor at 0.2, 0.4, and 0.6 mg/kg s.c. were given daily whereas minoxidil – a caveolin activator was given at 0.45 mg/kg, i.p. on alternate days for 28 days. STZ was also given at its submaximal dose 1.5 mg/kg to minoxidil group only. RESULTS: ICV-STZ control animals exhibited cognitive and neurological deficits on the Morris water maze, elevated plus maze, and balance beam tests (P < 0.0001). Treatment with daidzein significantly restored memory impairments and decreased oxidative damage whereas minoxidil potentiates the effect of STZ causing significant impairment in memory. Significant oxidative stress such as lipid peroxidation and glutathione (P < 0.0001) were also observed due to ICV-STZ administration resulting in neuronal damage which was significantly prevented by treatment with daidzein in brain tissues. CONCLUSION: The findings from the present investigation may conclude that the caveolin-1 from caveolae at the cell membrane induces memory deficits and oxidative stress phenotype that resemble the neurological phenotype of Alzheimer's disease. Further studies are warranted to gauge the effect of caveolin dyshomeostasis on the amyloidogenic cascade.

1 March 2024 in JCO Global Oncology
Verified
Journal Article
Open access
VHVarsha Hande
Varsha Hande
NRNilesh Ranjan
Nilesh Ranjan
SCSupriya Chopra
Supriya Chopra
SSShwetabh Sinha
Shwetabh Sinha
PMPrachi Mittal
Prachi Mittal
SGSudeep Gupta
Sudeep Gupta
PURPOSE: The PARCER trial provided level I evidence for image-guided intensity-modulated radiation therapy (IG-IMRT) in patients with cervical cancer. Further information regarding long-term financial impact is imperative for adoption into the National Cancer Grid of India cervical cancer resource-stratified guidelines. METHODS: Patient data from the PARCER trial were analyzed to evaluate the cost implications of transitioning to IG-IMRT. Lacking differences in outcomes between the three-dimensional conformal radiation (3D-CRT) and IG-IMRT, differences in treatment costs, adverse event incidence, and toxicity management costs were examined. The overall financial impact was estimated by adding the treatment costs, toxicity management, and wage loss. This was extrapolated nationally to determine if a transition to IG-IMRT would be feasible for the Indian health care system. RESULTS: Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in toxicity, respectively. The average toxicity management and the yearly financial impact per patient were, respectively, 1.50 and 1.44 times higher for 3D-CRT patients compared with IG-IMRT patients. Extrapolation to the national level showed that treatment with 3D-CRT led to a 2.88 times higher cost ratio when compared with treatment with IG-IMRT. CONCLUSION: Although the initial costs of IG-IMRT are high, on the basis of longitudinal data, it is financially inefficient to treat with 3D-CRT. Resource-stratified guidelines should include longitudinal health intervention costs rather than solely initial costs for policy decisions to implement advanced radiation technology.

28 November 2021 in JCO Global Oncology
Verified
Journal Article
Open access
AGAnkita Gupta
Ankita Gupta
TDTreshita Dey
Treshita Dey
BRBhavana Rai
Bhavana Rai
AOArun S. Oinam
Arun S. Oinam
SGSrinivasa Gy
Srinivasa Gy
SGSushmita Ghoshal
Sushmita Ghoshal
PURPOSE To evaluate the clinical outcomes in patients with cervical cancer with limited residual disease at brachytherapy (BT) treated with point-based dose prescription. METHODS Patients with locally advanced squamous cell carcinoma of the cervix treated with computed tomography (CT)-based intracavitary BT were considered for analysis. Patients with good response to external beam radiotherapy and limited residual disease suitable for intracavitary BT alone were included. Post-application CT scans were performed before each fraction and individual plans were made for each session. The dose per fraction was 9Gy high dose rate, prescribed to point-A. Two sessions were planned, 1 week apart. The organs at risk were contoured, and cumulative dose-volume histograms were computed. Local control, pelvic control, disease-free survival, and overall survival were evaluated and late toxicities were documented. RESULTS Four hundred ninety patients were included. Overall, 79.8% had International Federation of Gynecology and Obstetrics (FIGO) stage 162 to IIB disease and 20.2% had stage III to IVA disease. Median dose at point A (EQD2(10Gy)) was 74.4 Gy (interquartile range [IQRI 72.3-74.5 Gy) and median D-2cc (EQD2(3Gy)) for bladder, rectum, and sigmoid were 82.5 Gy (IQR, 65.5-90.8 Gy), 66.5 Gy (IQR, 60.7-75.7 Gy), and 54.1 Gy (IQR, 50.5-77.3 Gy), respectively. At a median follow-up of 62 (IQR, 33-87) months, the 5-year local and pelvic control rates were 90.1% and 88.3%, respectively. The 5-year disease-free survival was 80% and overall survival was 88%. Rates of grade 3-4 bladder and rectosigmoid toxicities were 6.93% and 4.08%, respectively. CONCLUSION In patients with limited residual disease at BT, point-based dose prescription with CT planning results in good local control and acceptable toxicity. In a resource-constrained setting, patients may be triaged to receive point-based BT or magnetic resonance imaging-guided adaptive BT depending on the extent of residual disease. (C) 2021 by American Society of Clinical Oncology

31 August 2020 in Indian Journal of Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
GSG. Y. Srinivasa
G. Y. Srinivasa
TDTreshita Dey
Treshita Dey
VSVanita Suri
Vanita Suri
RBRashmi Bagga
Rashmi Bagga
VJVanita Jain
Vanita Jain
SGSushmita Ghoshal
Sushmita Ghoshal

5 January 2021 in Indian Journal of Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
RMRenu Madan
Renu Madan
CDChinna Babu Dracham
Chinna Babu Dracham
AEArun Elangovan
Arun Elangovan
BRBhavana Rai
Bhavana Rai
GSG. Y. Srinivasa
G. Y. Srinivasa
SGSushmita Ghoshal
Sushmita Ghoshal